Is the Coherus Oncology (CHRS) investment thesis intact?

It is under pressure. Readouts currently rates the Coherus Oncology Thesis Challenged. Tagmokitug responses support esophageal expansion; durability and funding remain central.

What is the next catalyst for Coherus Oncology (CHRS)?

The next dated event is Phase 2 results for Casdozokitug, expected H2 2026, as stated by the company. Also ahead: Phase 1b start for Tagmokitug, expected Fall 2026.

How long will Coherus Oncology's cash last?

Coherus Oncology has said its cash will fund operations beyond Jun 2027 (guidance as of August 5, 2026).

CHRSCoherus Oncology, Inc.

Market reactionShares fell 12% on Nov 5.

ChallengedLast material event Aug 28, 2026 · Updated Oct 29, 2026

Tagmokitug responses support esophageal expansion; durability and funding remain central

Coherus Oncology sells LOQTORZI, an approved immunotherapy for nasopharyngeal cancer licensed from Junshi, and is developing tagmokitug and casdozokitug, two unapproved cancer antibodies.

Coherus combines growing LOQTORZI sales with investigational antibody combinations. Tagmokitug's strongest early signal is in first-line esophageal cancer with toripalimab and chemotherapy, supporting expansion, but its added benefit and durability remain uncertain. Casdozokitug's randomized liver cancer readout remains important. Commercial growth has not eliminated losses or financing dependence; the debt refinancing improves flexibility, while transition-related obligations limit available cash.

Thesis checklist

1 risk needs attention

Select a row for evidence

What must be trueStateNext proof

Tagmokitug shows activityAwaiting evidenceExpanded ESCC cohorts with longer response duration, progression-free survival and safety follow-up.Next: Expanded ESCC cohorts with longer response duration, progression-free survival and safety follow-up.

Why it is in this state

The evidence, what would weaken it and the source filing

Casdozokitug improves liver cancer outcomesAwaiting evidenceFirst randomized Phase 2 results, expected 2H 2026.Next: First randomized Phase 2 results, expected 2H 2026.

Why it is in this state

The evidence, what would weaken it and the source filing

LOQTORZI keeps growingSupportedNext quarterly revenue, patient starts and therapy-duration trends.Next: Next quarterly revenue, patient starts and therapy-duration trends.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash and debt fund the planAt riskUpdated cash, operating cash use and financing utilization after refinancing.Next: Updated cash, operating cash use and financing utilization after refinancing.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Can expanded ESCC results strengthen tagmokitug's clinical value?

Tests: Tagmokitug shows activity

At the next expanded-cohort update with longer follow-up

Will larger ESCC cohorts sustain responses and acceptable tolerability while clarifying tagmokitug's contribution to the combination?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

ChallengedCurrentFinancial

-4.3%Aug 28, 2026

Tagmokitug responses support esophageal expansion; durability and funding remain central

ChallengedCommercial

-12.3%May 11, 2026

LOQTORZI's commercial trajectory toward $150-200M by 2028 is the thesis; pipeline optionality in casdozokitug and tagmokitug determines whether this becomes a multi-asset story

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Castration-resistant prostate cancer

Tagmokitug · 1 upcoming

Phase 1b Study Initiation

Fall 2026

Hepatocellular carcinoma· first-line unresectable

Casdozokitug · 1 upcoming

Phase 2 Data

H2 2026

Nasopharyngeal carcinoma· advanced

LOQTORZI · 1 upcoming

Enrollment: Completion

TBD

Esophageal squamous cell carcinoma· first-line

Tagmokitug · 1 upcoming

Phase 1b Data: UpdateTREGCHECK 102

TBD

Esophageal squamous cell carcinoma· second-line

Tagmokitug · 1 upcoming

Phase 1b Data: UpdateTREGCHECK 102

TBD

Solid tumors· HNSCC, upper GI adenocarcinoma, CRC

Tagmokitug · 1 completed

Phase 1b Data: Interim

Reported Oct 28, 2026

Esophageal squamous cell carcinoma· 1L and 2L

Tagmokitug · 1 completed

Phase 1b Data: Interim

Reported Oct 28, 2026

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Coherus Oncology (CHRS) investment thesis intact?: It is under pressure. Readouts currently rates the Coherus Oncology Thesis Challenged. Tagmokitug responses support esophageal expansion; durability and funding remain central.
What is the next catalyst for Coherus Oncology (CHRS)?: The next dated event is Phase 2 results for Casdozokitug, expected H2 2026, as stated by the company. Also ahead: Phase 1b start for Tagmokitug, expected Fall 2026.
How long will Coherus Oncology's cash last?: Coherus Oncology has said its cash will fund operations beyond Jun 2027 (guidance as of August 5, 2026).

Other companies we cover in these diseases

Head and neck squamous cell carcinoma: Immutep (IMMP)Pyxis Oncology (PYXS)
Hepatocellular carcinoma: MAIA Biotechnology (MAIA)
Prostate cancer: INmune Bio (INMB)
Colorectal cancer: Cardiff Oncology (CRDF)

Disease areas: Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

26 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.